Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-finding study of BMS-986470 in healthy volunteers and adults with sickle cell disease
2023-510283-12-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Modality
- Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing BMS-986470 with Placebo (2 arms). Planned start Jun 2025; status: authorised.
02
Drugs
BMS-986470
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2023-510283-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510283-12-00.